Atea Pharmaceuticals, Inc. (AVIR)

NASDAQ: AVIR · USD

$4.22

+0.05 (+1.2%)· Recorded snapshot

Market cap	338.5M
Net income (ttm)	-165.3M
EPS (ttm)	-$2.10
Shares out	80.2M
Volume	267,156
Beta	0.39

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -165.3M
EPS (ttm): -$2.10
Market cap: 338.5M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Aanhouden

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-58.1

P25 n/aP50 n/aP75 n/a

ROIC-40.2

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All AVIR indicators

Market & fundamental data

Available fields

182

Groups with data

Currency

USD

Showing 182 of 182 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001593899
Company name	Atea Pharmaceuticals, Inc.
Country	United States
Country code	US
CUSIP number	04683R106
Earnings date	2026-11-11
Earnings time	amc
Employees	55
Employees change	-1
Employees growth	-1.79%
Enterprise value	$119.4M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2012
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2020-10-30
Is primary listing	Yes
Is SPAC	No
ISIN number	US04683R1068
Last 10-K release date	2026-03-05
Last earnings date	2026-08-12
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$338.5M
Market cap category	Small-Cap
Next earnings date	2026-11-11
Options	Yes
Price	$4.22
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	AVIR
U.S. state	Massachusetts
Website	https://ateapharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-49.67%
FCF / EV yield	-128.2%
FCF yield	-45.04%
P/B ratio	1.64x
Price / tangible book value	1.65x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-3M
ROA	-36.72%
ROA (5Y)	-11.07%
ROCE	-89.77%
ROE	-58.14%
ROE (5Y)	-19.77%
ROIC	-40.17%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	1
EPS growth years	1
Net income growth quarters	1
Net income growth years	1
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Depreciation and amortization	$416,000
EBIT	$-183.3M
EBITDA	$-182.9M
EPS	$-2.10
FCF per share	$-1.90
Financing cash flow	$-11M
Free cash flow	$-152.1M
Free cash flow minus SBC	$-168.3M
Gross profit	$-155.1M
Income taxes	$-6.5M
Investing cash flow	$151.9M
Net cash flow	$-11.2M
Net income	$-165.3M
Operating cash flow minus SBC	$-168.3M
Operating income	$-183.3M
Stock-based compensation	$16.2M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$2.55
Debt / equity	0
Long-term assets	$3.6M
Long-term liabilities	$0
Net cash (debt)	$219M
Net cash / market cap	64.87%
Net cash growth	-42.12%
Net debt / equity	-1.07
Piotroski F-Score	1
Property, plant and equipment	$569,000
Shareholders' equity	$204.2M
Tangible book value	$204.2M
Tangible book value per share	$2.55
Total assets	$232.3M
Total cash	$219.5M
Total debt	$424,000
Total liabilities	$28.1M
WACC	6.38%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$228.7M
Current liabilities	$28.1M
Current ratio	8.13
Net working capital	$-18.5M
Quick ratio	7.8
Working capital	$200.5M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	6.62%
Dividend yield	0%
Shareholder yield	6.62%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$5.00
1D price change	1.2%
1M price change	-18.76%
1M total return	-18.76%
1W price change	-5.94%
1W total return	-5.94%
1Y price change	29.23%
1Y return CAGR	29.25%
1Y total return	29.23%
20-day SMA	$4.64
200-day SMA	$4.92
3M price change	-12.86%
3M total return	-12.86%
3Y price change	36.36%
3Y return CAGR	10.89%
3Y total return	36.36%
50-day SMA	$5.09
50-day SMA vs 200-day SMA	50over200
52-week high	$6.45
52-week high date	2026-03-10
52-week low	$2.87
52-week low date	2025-11-13
5Y price change	-65.49%
5Y return CAGR	-19.17%
5Y total return	-65.49%
6M price change	-21.64%
6M total return	-21.64%
All-time high	$94.17
All-time high date	2021-02-11
All-time low	$2.46
All-time low date	2025-05-15
Average true range (ATR)	$0.23
Average volume	296.6K
Beta (1Y)	1.19
Beta (2Y)	0.65
Beta (5Y)	0.39
Change from 52-week high	-34.57%
Change from 52-week low	47.04%
Change from all-time high	-95.54%
Change from all-time low	71.08%
Change from open	1.2%
Day's gap	0%
Dollar volume	$1.1M
High price	$4.24
Low price	$4.15
Monthly RSI	47.65
Open price	$4.17
Position in 52-week range	82.35%
Premarket change	0.97%
Premarket close	$4.17
Premarket price	$4.21
Previous close	$4.17
Price vs 150-day SMA	-15.95%
Price vs 20-day SMA	-9.48%
Price vs 200-day SMA	-14.65%
Price vs 50-day SMA	-17.53%
Relative volume	0.9
Return from IPO open	-84.42%
Return from IPO price	-82.46%
RSI	32.18
Sharpe ratio	0.68
Sharpe ratio (3Y)	0.41
Sharpe ratio (5Y)	-0.23
Sortino ratio	1.07
Sortino ratio (3Y)	0.72
Sortino ratio (5Y)	-0.23
Volume	267.2K
Weekly RSI	41.35
YTD price change	17.65%
YTD total return	17.65%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	60.3M
Float percentage	75.23%
Shares change (QoQ)	1.08%
Shares change (YoY)	-6.62%
Shares held by insiders	16.1%
Shares held by institutions	67.87%
Shares outstanding	80.2M
Short % of float	5.09%
Short % of shares	3.83%
Short ratio	27 days

Deeper analysis on AVIR

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this AVIR report

Is a complete AVIR research report available?

No complete published report is available for Atea Pharmaceuticals, Inc. (AVIR) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Atea Pharmaceuticals, Inc. (AVIR)

Price

Financial snapshot

Fair-value bridge

Latest news · AVIR

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All AVIR indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on AVIR

Frequently asked questions